



This email is intended for Facility and Group users of the Long-term Care Facility (LTCF) Component of NHSN.

Below is important information for the Long-term Care Facility COVID-19 Module regarding modifications for the NHSN release that will occur February 2022. Resources on the [NHSN LTCF COVID-19 Module website](#) will be updated, where indicated, with revised forms, instructions, FAQs and CSV templates. Information regarding training opportunities is also available on the NHSN LTCF COVID-19 Module Website.

Point of Care (POC) Test Reporting Tool:

No Enhancements

COVID-19 Pathway Data Reporting:

Please refer to the below data reporting pathways to learn about enhancements that will be made within each pathway.

Resident Impact and Facility Capacity Pathway:

No enhancements

Staff and Personnel Impact Pathway:

No enhancements

Supplies and Personal Protective Equipment (PPE) Pathway:

No enhancements

Therapeutics Pathway:

There will be an update that will categorize the listed Therapeutics by medication type. The form posted to the NHSN COVID-19 Module webpage will also be updated to reflect this change. Please see below.

Add COVID-19 Data

Date for which counts are reported: _____ Facility CCN: _____ Facility Type: _____

Resident Impact and Facility Capacity Staff and Personnel Impact Supplies and Personal Protective Equipment **Therapeutics**

Date Created: _____

Report total counts for the below questions only one calendar day during the reporting week and include only new counts since the previously report if the count is zero, a "0" must be entered as the response. A blank response is equivalent to missing data.

For each therapeutic listed, enter number of residents who received the therapeutic at this facility or elsewhere during the reporting week:

Therapeutic	How many residents were treated from stock stored at this facility?	How many residents were treated from stock that was stored at another facility, such as an infusion center?
Monoclonal Antibody Therapy		
Casirivimab/Imdevimab (Regeneron)	<input type="text"/>	<input type="text"/>
Bamlanivimab/etesevimab (Lilly)	<input type="text"/>	<input type="text"/>
Sotrovimab (GlaxoSmithKline)	<input type="text"/>	<input type="text"/>
Evusheld (AstraZeneca)	<input type="text"/>	<input type="text"/>
Antiviral Therapy		
Paxlovid (Pfizer)	<input type="text"/>	<input type="text"/>
Molnupiravir (Merck)	<input type="text"/>	<input type="text"/>

State Veterans Homes COVID-19 Event Reporting Tool

Newly Food and Drug Administration (FDA) approved COVID-19 therapeutic and prophylactic medications will be added to the SVH COVID-19 Event Reporting Tool. Resources on the [SVH COVID-19 Event Reporting Tool webpage](#) will be updated, where indicated, with revised forms, instructions, and FAQs to assist you.

The following therapeutics will be added to the NHSN SVH COVID-19 Event Reporting Tool:

Evusheld (AstraZeneca)
 Paxlovid (Pfizer)
 Molnupiravir (Merck)

The reporting guidance has not changed for this reporting tool. Please continue to use the SVH Event Reporting Tool table of instructions to indicate administration to residents.

Weekly NHSN COVID-19 Vaccination Data Modules

- The question on individuals eligible for an additional dose or booster dose (currently question 4 on the data collection) will be removed since most individuals are now eligible for a booster dose according to latest CDC guidelines ([Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#)). This will also simplify data reporting for facilities.
- Previously, CDC instructed facilities not to include vendors as healthcare personnel. After receiving stakeholder feedback, CDC has updated COVID-19 vaccination data reporting guidance to include vendors under the "other contract personnel" category if they are regularly scheduled to work in the facility, regardless of clinical responsibility or patient contact. Facilities should now begin reporting data on vendors from this point forward. If possible, facilities should revise data reported for prior weeks in accordance with this new guidance. For more information, please see the updated frequently asked questions, specifically questions 14 and 15, under the

“Data Reporting: General” section: [FAQs on Reporting COVID-19 Vaccination Data | NHSN | CDC](#).

For questions about any of these updates, please send an e-mail to the NHSN Helpdesk at NHSN@cdc.gov with the subject line identifying the topic in the subject line of the message.

Thank you for your partnership,
The NHSN LTCF Team